ORKA-001 — Full data
Dec 2026
In addition, Oruka expects to share 52-week results from EVERLAST-A in December 2026, as well as 52-week results from EVERLAST-B in the second half of 2027.Source filing
ORKA biotech catalysts & pipeline
ORUKA THERAPEUTICS INC · Data as of 2026-10-27
Upcoming catalysts
ORKA-002 — Initial data
1Q 2027
ORKA-002 16-week results from ORCA-SURGE Phase 2 in psoriasis on track for 1Q 2027Source filing
ORKA-002 — Clinical data readout
Q1 2027
The Company now expects to report Week 16 data from ORCA-SURGE, a Phase 2 trial in moderate-to-severe PsO, in the first quarter of 2027.Source filing
ORKA-001 — Full data
H2 2027
In addition, Oruka expects to share 52-week results from EVERLAST-A in December 2026, as well as 52-week results from EVERLAST-B in the second half of 2027.Source filing
ORKA-001 — Clinical data readout
Q3 2026
The Company expects to report Week 28 data from EVERLAST-A for all participants at the end of the third quarter of 2026.Source filing
ORKA-001 — Full data
Q3 2026
We plan to share Week 28 data from all patients at the end of the third quarter of 2026.Source filing